Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SynKIR-310 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on SynKIR-310, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (Nov 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SynKIR-310 | SynKIR 310|SynKIR310 | CD19 Immune Cell Therapy 72 | Limited information is currently available on SynKIR-310, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (Nov 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06544265 | Phase I | SynKIR-310 | SynKIR-310 for Relapsed/Refractory B-NHL | Recruiting | USA | 0 |